Profile: Peregrine Pharmaceuticals, Inc. develops and manufactures monoclonal antibodies for the treatment of cancer and serious viral infections. Our Bavituximab anti-cancer is a monoclonal antibody that targets a basic component of a cell's membrane called phosphatidylserine (PS). It alerts the body's immune system to attack the tumor blood vessel cells that exhibit exposed PS. It is currently in two separate phase I combination therapy trials for the treatment of advanced breast cancer and a phase II combination therapy trial for the treatment of non-small cell lung cancer. We offer a broad-spectrum of antibodies to treat and prevent infectious diseases.

The company has revenues of < USD 1 Million, has ~30 employees.